146 related articles for article (PubMed ID: 30557902)
21. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses.
Klein RL; McHenry MB; Lok KH; Hunter SJ; Le NA; Jenkins AJ; Zheng D; Semler AJ; Brown WV; Lyons TJ; Garvey WT;
Metabolism; 2004 Oct; 53(10):1296-304. PubMed ID: 15375785
[TBL] [Abstract][Full Text] [Related]
22. Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status.
Peacock RE; Temple A; Gudnason V; Rosseneu M; Humphries SE
Genet Epidemiol; 1997; 14(3):265-82. PubMed ID: 9181356
[TBL] [Abstract][Full Text] [Related]
23. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
Chiuve SE; Martin LA; Campos H; Sacks FM
J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
[TBL] [Abstract][Full Text] [Related]
24. ApoCIII: A multifaceted protein in cardiometabolic disease.
D'Erasmo L; Di Costanzo A; Gallo A; Bruckert E; Arca M
Metabolism; 2020 Dec; 113():154395. PubMed ID: 33058850
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation.
Kawakami A; Osaka M; Aikawa M; Uematsu S; Akira S; Libby P; Shimokado K; Sacks FM; Yoshida M
Circ Res; 2008 Dec; 103(12):1402-9. PubMed ID: 18974386
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death.
Paiva AA; Raposo HF; Wanschel AC; Nardelli TR; Oliveira HC
Oxid Med Cell Longev; 2017; 2017():1838679. PubMed ID: 28163820
[TBL] [Abstract][Full Text] [Related]
27. Structure and dynamics of human apolipoprotein CIII.
Gangabadage CS; Zdunek J; Tessari M; Nilsson S; Olivecrona G; Wijmenga SS
J Biol Chem; 2008 Jun; 283(25):17416-27. PubMed ID: 18408013
[TBL] [Abstract][Full Text] [Related]
28. DNA polymorphisms at the apolipoprotein A1-CIII loci in Taiwanese: correlation of plasma APOCIII with triglyceride level and body mass index.
Wu JH; Kao JT; Wen MS; Lo SK
J Formos Med Assoc; 2000 May; 99(5):367-74. PubMed ID: 10870325
[TBL] [Abstract][Full Text] [Related]
29. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease.
Lee SJ; Moye LA; Campos H; Williams GH; Sacks FM
Atherosclerosis; 2003 Apr; 167(2):293-302. PubMed ID: 12818412
[TBL] [Abstract][Full Text] [Related]
30. Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII.
Recio-López P; Valladolid-Acebes I; Hadwiger P; Hossbach M; Krampert M; Prata C; Berggren PO; Juntti-Berggren L
Biofactors; 2023 Jan; 49(1):153-172. PubMed ID: 36039858
[TBL] [Abstract][Full Text] [Related]
31. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children.
Shoulders CC; Grantham TT; North JD; Gaspardone A; Tomai F; de Fazio A; Versaci F; Gioffre PA; Cox NJ
Hum Genet; 1996 Nov; 98(5):557-66. PubMed ID: 8882875
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein CIII reduces proinflammatory cytokine-induced apoptosis in rat pancreatic islets via the Akt prosurvival pathway.
Størling J; Juntti-Berggren L; Olivecrona G; Prause MC; Berggren PO; Mandrup-Poulsen T
Endocrinology; 2011 Aug; 152(8):3040-8. PubMed ID: 21693679
[TBL] [Abstract][Full Text] [Related]
33. Human apolipoprotein CIII levels; evaluation of three assay methods.
Sandin Å; Olofsson C; Strålfors A; Rajamand Ekberg N; Brismar K; Juntti-Berggren L; Eggertsen G
Scand J Clin Lab Invest; 2020 May; 80(3):230-235. PubMed ID: 32108506
[TBL] [Abstract][Full Text] [Related]
34. VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.
Botteri G; Montori M; Gumà A; Pizarro J; Cedó L; Escolà-Gil JC; Li D; Barroso E; Palomer X; Kohan AB; Vázquez-Carrera M
Diabetologia; 2017 Nov; 60(11):2262-2273. PubMed ID: 28835988
[TBL] [Abstract][Full Text] [Related]
35. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
Zhang J; Rocha NA; McCullough PA
Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice.
van der Hoogt CC; Berbée JF; Espirito Santo SM; Gerritsen G; Krom YD; van der Zee A; Havekes LM; van Dijk KW; Rensen PC
Biochim Biophys Acta; 2006 Feb; 1761(2):213-20. PubMed ID: 16478678
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice.
Takahashi T; Hirano T; Okada K; Adachi M
Metabolism; 2003 Oct; 52(10):1354-9. PubMed ID: 14564689
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.
Katzmann JL; Werner CM; Stojakovic T; März W; Scharnagl H; Laufs U
Lipids Health Dis; 2020 May; 19(1):116. PubMed ID: 32473635
[TBL] [Abstract][Full Text] [Related]
40. Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis.
Han Y; Qi R; Liu G
Biochem Biophys Res Commun; 2015 Jul; 462(4):420-5. PubMed ID: 25969427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
